Nadim Ahmed - 22 Feb 2024 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role: President and CEO, Director
Signature: /s/ Jacquelyn Sumer, Attorney-in-Fact
Issuer symbol: CGEM
Transactions as of: 22 Feb 2024
Transactions value $: $0
Form type: 4
Date filed: 23 Feb 2024, 17:00
Previous filing: 27 Dec 2023
Next filing: 27 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CGEM	Common Stock	Award	$0	+160K	+143.43%	$0.00	272K	22 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CGEM	Stock Option (Right to Buy)	Award	$0	+320K		$0.00	320K	22 Feb 2024	Common Stock	320K	$17.54	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying the restricted stock unit vest on an annual basis over four years.
F2	The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.